Innovent has submitted a second new drug application (NDA) to China's National Medical Products Administration (NMPA) seeking approval for Dovbleron as a treatment for ROS1-positive advanced NSCLC ...

The grants, awarded in partnership with the Authority of Social Contribution-Ma'an, will fund 11 research projects across multiple disease areas.

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.

The Congressional Budget Office said policies to increase treatment uptake could affect Medicaid, Social Security, and other government programs.

Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

The firm said it plans to share data with regulatory agencies from the Phase III STEER trial after it met its primary endpoint.

Concr will use data collected by CariGenetics to create AI models to advance precision medicine for triple-negative breast cancer patients in the Caribbean.

NEW YORK – Carsgen Therapeutics on Monday said it plans to seek approval in China for its autologous CAR T-cell therapy satricabtagene autoleucel (satri-cel) in previously treated patients with ...

To be eligible for the firm's half-life extended ImmTAC therapy, patients must be HLA-A*02:01-positive and have advanced solid cancers expressing PRAME.

The transaction, expected to close in the first half of 2025, will not affect the firm's other contract research business units.